Company intelligence / Profile preview
Curis, Inc.
Lexington, Massachusetts, United Statescuris.com ↗
- Ownership
- Public · CRIS
- Employees
- ~33
- Development stage
- Phase 2
01
Overview
Curis’s lead asset is emavusertib (CA‑4948), an oral IRAK4 inhibitor in multiple Phase 1/2 studies for relapsed/refractory PCNSL and AML/MDS. Emavusertib has received Orphan Drug Designation for PCNSL in the US and EU. The company also has a commercial-stage product—Erivedge®—licensed to Genentech/Roche for advanced basal cell carcinoma. Other pipeline assets are at earlier stages or deprioritized.[6][2]
- Therapeutic areas
- HematologyOncology
- Modalities
- Small molecules[3][6]
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Request access →03
Partnerships
Aurigene Discovery Technologies Limited — exclusive license for emavusertib and other pipeline assets.Genentech/Roche — Erivedge licensed out for commercialization.National Cancer Institute — research collaboration.[6][5][3]
04
Financials
- Market cap
- $2.3M
- Total revenue
- $0
- Enterprise value
- $-2.2M
Beyond the preview
Go deeper on Curis, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Curis, Inc..